Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients

Figures & data

Table 1 Distribution of parotid gland cancers

Cancer subtype	n (%)
High grade (n=37)
Parotid duct carcinoma	14 37.8%
Mucoepidermoid carcinoma	19 51.4%
Spindle cell carcinoma	1 2.7%
Adenocarcinoma not otherwise specified	2 5.4%
Small cell carcinoma	1 2.7%
Intermediate grade (n=89)
Mucoepidermoid carcinoma	64 71.9%
Adenoid cystic carcinoma	22 24.7%
Myoepithelial cancer	3 3.4%
Lower grade (n=123)
Mucoepidermoid carcinoma	84 68.3%
Acinic cell cancer	20 16.3%
Pleomorphic low grade adenocarcinoma	6 4.9%
Epithelial-myoepithelial carcinoma	8 6.5%
Basal cell adenocarcinoma	5 4.1%

Table 2 Association between neutrophil-to-lymphocyte ratio and clinical pathologic variables

	Neutrophil-to-lymphocyte ratio		P-value
Variables	<2.48 (n=111)	≥2.48 (n=138)
Age, years
<50	47	63
≥50	64	75	0.601
Sex
Female	71	76
Male	40	62	0.156
Tumor stage
T1+ T2	73	69
T3+ T4	38	69	0.012
Node stage
N0	85	104
N+	26	34	0.824
Disease stage
I+II	61	56
III + IV	50	82	0.024
Perineural invasion
Positive	11	20
Negative	100	118	0.276
Lymphovascular invasion
Positive	9	16
Negative	102	`122	0.363
Intraparotid node metastasis
Positive	21	24
Negative	90	114	0.756
Tumor Grade
Low	63	60
Intermediate	40	49
High	8	29	0.006

Figure 1 Disease-specific survival in patients with different NLRs.

Note: P=0.006.

Abbreviation: NLR, neutrophil-to-lymphocyte ratio.

Table 3 Univariate and multivariate analysis of the predictors for disease-specific survival in patients with parotid cancer

Variables	Univariate	Cox model
	P-value	P-value	OR (95% CI)
Age, years (<50 vs ≥50)	0.246
Sex (Female vs male)	0.167
Tumor stage (T1+ T2 vs T3+ T4)	0.004	0.087	2.647 (0.913–5.688)
Node stage (N0 vs N+)	0.002	0.123	1.997 (0.798–4.754)
Disease stage (I+II vs III+IV)	<0.001	0.002	2.114 (1.467–6.337)
Perineural invasion	<0.001	0.222	3.135 (0.687–7.541)
Lymphovascular invasion	<0.001	<0.001	2.874 (1.226–7.684)
Intraparotid node metastasis	0.013	0.003	1.845 (1.054–4.531)
NLR (<2.48 vs ≥2.48)	0.006	0.016	1.223 (1.013–2.442)
Disease grade	<0.001
Low
Intermediate		0.187	2.113 (0.906–7.221)
High		0.017	3.269 (1.678–10.336)
Radiotherapy	0.458
Chemotherapy	0.367
Herceptin	0.088

Abbreviation: NLR, neutrophil-to-lymphocyte ratio.